Eli Lilly and Company (NYSE:LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $875.00.
The rating update came after Eli Lilly and Company reported its fiscal Q2 2025 earnings on August 7, with revenue growing 38% to $15.56 billion, driven primarily by volume growth from Zepbound and Mounjaro.
Eli Lilly and Company raised the midpoint of its 2025 full-year revenue guidance by $1.5 billion, taking it to the $60 billion to $62 billion range. It also raised its reported EPS guidance to be in the $20.85 to $22.10 range.
Eli Lilly and Company develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
